Market closedNon-fractional
Nurix Therapeutics/NRIX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Ticker
NRIX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Francisco, United States
Employees
284
Website
www.nurixtx.com
NRIX Metrics
BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$2.92
EPS
2.22
Beta
-
Dividend rate
Price and volume
Market cap
$1.4B
Beta
2.22
Financial strength
Current ratio
5.573
Quick ratio
5.493
Long term debt to equity
5.634
Total debt to equity
7.774
Management effectiveness
Return on assets (TTM)
-25.98%
Return on equity (TTM)
-52.33%
Valuation
Price to revenue (TTM)
19.113
Price to book
3.68
Price to tangible book (TTM)
3.68
Price to free cash flow (TTM)
-11.237
Growth
Revenue change (TTM)
2.25%
Earnings per share change (TTM)
-1.33%
3-year revenue growth (CAGR)
39.65%
3-year earnings per share growth (CAGR)
4.14%
What the Analysts think about NRIX
Analyst Ratings
Majority rating from 12 analysts.
NRIX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$17M
9.27%
Net income
-$42M
-0.95%
Profit margin
-251.51%
-9.36%
NRIX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.68
-$0.77
-$0.76
-
Expected
-$0.56
-$0.76
-$0.57
-$0.80
-$0.65
Surprise
-19.64%
-10.03%
35.09%
-5.24%
-
NRIX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $1.4B as of July 26, 2024.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of July 26, 2024.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Nurix Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.